Penumbras Blood Clot Device Trial Recruits First Participant

The trials set out to compare anticoagulation plus Lightning Flash versus only anticoagulation in the treatment of pulmonary embolism. Penumbra has recently recruited their first participant. 

The thrombectomy system is crafted to extract emboli (a blood clot or air bubble) and thrombi (a fatty material that builds up) from within blood vessels.
Penumbras device combines Indigo Aspiration Catheters with the Lightning Intelligent Aspiration system to minimize blood loss and lessen reliance on clot-dissolving medications. 

Pulmonary embolism presents a critical, life-threatening risk, with a mortality rate of 10%-30% within 5 weeks of detection. In the United States, around 900,000 cases of symptomatic PE are reported annually. 

James Beneati, leading marketing body, stated, “Our commitment to clinical research and innovation enables us to lead with insight and continue to pioneer interventional therapies that have a significant impact on patients such as our CAVT technologies.” 

Beneati went on to add, “In partnership with PERT Consortium, we are committed to generating robust clinical evidence that will help transform care so patients, especially those with serious conditions such as PE, can return home quickly and live fully.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.